Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00074
|
|||||
| Drug Name |
Allopurinol
|
|||||
| Synonyms |
4-HPP; A 8003; AL-100; Adenock; Ailural; Ailurial; Allo-Puren; Allohexal; Allohexal (TN); Allohexan; Alloprin; Allopur; Allopurin; Allopurinol(I); Allopurinolum; Allorin; Allosig (TN); Allozym; Allpargin; Allural; Aloprim; Alopurinol; Aloral; Alositol; Aluline; Anoprolin; Anzief; Apo-Allopurinol; Apulonga; Apurin; Apurol; Atisuril; B. W. 56-158; BW 56-158; BW 56158; BW-56-158; Bleminol; Bloxanth; Caplenal; Capurate; Cellidrin; Cosuric; Dabrosin; Dabroson; Dura Al; Embarin; Epidropal; Epuric; Foligan; Geapur; Gichtex; Gotax; Hamarin; Hexanuret; Jenapurinol; Ketanrift; Ketobun-A; Ledopur; Lopurin; Lysuron; Milurit; Milurite; Miniplanor; Monarch; Nektrohan; Novopurol; Pan Quimica; Progout; Progout (TN); Pureduct; Puricos (TN); Purinol; Quimica, Pan; Remid; Riball; Rimapurinol; Roucol; Sigapurol; Suspendol; Takanarumin; Tipuric; Urbol; Uribenz; Uricemil; Uridocid; Uriprim; Uripurinol; Uritas; Urobenyl; Urolit; Urosin; Urtias; Urtias 100; Xanthomax; Xanturat; Xanturic; Zygout; Zyloprim; Zyloprim (TN); Zyloric; Zyloric (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hyperuricaemia [ICD11:5C55.Y] | Approved | [1] | |||
| Therapeutic Class |
Antimetabolites
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C5H4N4O
|
|||||
| Canonical SMILES |
C1=NNC2=C1C(=O)NC=N2
|
|||||
| InChI |
InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
|
|||||
| InChIKey |
OFCNXPDARWKPPY-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 315-30-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 136.11 | Topological Polar Surface Area | 70.1 | ||
| Heavy Atom Count | 10 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
-0.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321496
,10518263
,11110781
,11335860
,11361099
,11362800
,11365362
,11367924
,11371398
,11373689
,11376086
,11449337
,11462071
,11483792
,11487914
,11490105
,11491950
,11493840
,15119988
,15146664
,17389550
,17404665
,22395219
,24278141
,26611594
,26679243
,26697339
,26747845
,26747846
,29221274
,3133506
,3727085
,404525
,4266415
,42880554
,46508516
,47440268
,47589009
,47737041
,48259236
,4826301
,48415533
,48422551
,594917
,6262863
,68199
,7348782
,7836064
,8139898
,8149190
|
|||||
| ChEBI ID |
ChEBI:40279
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OAT2 | Transporter Info | Organic anion transporter 2 | Substrate | [2] | |
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [3] | ||
| References | ||||||
| 1 | Allopurinol was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. | |||||
| 3 | Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.